DK1326630T3 - Anvendelse af GLP-2-peptider - Google Patents
Anvendelse af GLP-2-peptiderInfo
- Publication number
- DK1326630T3 DK1326630T3 DK01982302T DK01982302T DK1326630T3 DK 1326630 T3 DK1326630 T3 DK 1326630T3 DK 01982302 T DK01982302 T DK 01982302T DK 01982302 T DK01982302 T DK 01982302T DK 1326630 T3 DK1326630 T3 DK 1326630T3
- Authority
- DK
- Denmark
- Prior art keywords
- glp
- peptides
- hyperparathyroidism
- glucagon
- analogues
- Prior art date
Links
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 title abstract 2
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 title 1
- 201000002980 Hyperparathyroidism Diseases 0.000 abstract 1
- 102100040918 Pro-glucagon Human genes 0.000 abstract 1
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0022844A GB0022844D0 (en) | 2000-09-18 | 2000-09-18 | Use of GLP-1 and GLP-2 peptides |
GB0029920A GB0029920D0 (en) | 2000-12-07 | 2000-12-07 | Use of glp-1 and glp-2 peptides |
PCT/EP2001/010714 WO2002022151A2 (en) | 2000-09-18 | 2001-09-17 | Use of glp-1 and flp-2 peptides for treatment of bone disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1326630T3 true DK1326630T3 (da) | 2008-09-15 |
Family
ID=26245018
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01982302T DK1326630T3 (da) | 2000-09-18 | 2001-09-17 | Anvendelse af GLP-2-peptider |
DK01967517.2T DK1414486T3 (da) | 2000-09-18 | 2001-09-18 | Anvendelse af GLP-2 i kombination med et andet terapeutisk middel ved knoglerelaterede sygdomme |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01967517.2T DK1414486T3 (da) | 2000-09-18 | 2001-09-18 | Anvendelse af GLP-2 i kombination med et andet terapeutisk middel ved knoglerelaterede sygdomme |
Country Status (11)
Country | Link |
---|---|
US (2) | US6770620B2 (da) |
EP (3) | EP1326630B1 (da) |
JP (2) | JP5161412B2 (da) |
AT (2) | ATE396738T1 (da) |
AU (2) | AU2002213925A1 (da) |
CY (2) | CY1108263T1 (da) |
DE (2) | DE60134251D1 (da) |
DK (2) | DK1326630T3 (da) |
ES (2) | ES2310192T3 (da) |
PT (2) | PT1326630E (da) |
WO (2) | WO2002022151A2 (da) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070135345A1 (en) * | 2000-09-18 | 2007-06-14 | Henriksen Dennis B | Use of GLP-2 for the treatment or prevention, of bone-related disorders |
US7371721B2 (en) * | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
US7186683B2 (en) * | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
US20080249016A1 (en) * | 2000-09-18 | 2008-10-09 | Sanos Bioscience A/S | Use of GLP-2 in a combination treatment for bone-related disorders |
DE60134251D1 (de) * | 2000-09-18 | 2008-07-10 | Sanos Bioscience As | Verwendung von glp-2-peptiden |
RO120121B1 (ro) * | 2000-12-18 | 2005-09-30 | Elena Ionaşcu | Soluţie injectabilă, cu efect antiinflamator, procedeu de obţinere şi metodă de tratament a bolilor autoimune |
CA2372450A1 (en) * | 2001-05-10 | 2001-09-19 | Pharmaceutical Partners Of Canada Inc. | Liquid injectable formulation of disodium pamidronate |
DE10135315A1 (de) * | 2001-07-19 | 2003-01-30 | Bayer Ag | Stents |
ES2545090T3 (es) | 2001-12-21 | 2015-09-08 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina y GCSF |
MXPA04011203A (es) | 2002-05-17 | 2005-07-14 | Univ Duke | Metodo para tratar la obesidad. |
US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
WO2004084859A2 (en) | 2003-03-21 | 2004-10-07 | Nastech Pharmaceutical Company Inc. | Nasal calcitonin formulations containing chlorobutanol |
JP2007525425A (ja) * | 2003-03-24 | 2007-09-06 | ノボ ノルディスク アクティーゼルスカブ | Glp−2誘導体 |
EP1870096A3 (en) * | 2003-04-29 | 2011-04-20 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
EP2316456B1 (en) * | 2003-04-29 | 2017-06-14 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss comprising an opioid antagonist and bupropion |
ES2383752T3 (es) | 2003-05-15 | 2012-06-26 | Trustees Of Tufts College | Analogos estables de GLP-1 |
US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
CA2553207A1 (en) * | 2004-01-13 | 2005-08-04 | Kishore M. Gadde | Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss |
JP2007536229A (ja) * | 2004-05-03 | 2007-12-13 | デューク・ユニバーシティー | 体重減少に作用するための組成物 |
ATE498631T1 (de) * | 2005-05-04 | 2011-03-15 | Zealand Pharma As | Glucagon-like-peptide-2- (glp-2-) analoga |
WO2006135660A2 (en) * | 2005-06-10 | 2006-12-21 | University Of Chicago | Therapies involving lymphotoxin beta receptor |
WO2007067341A2 (en) * | 2005-11-22 | 2007-06-14 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
CA2651283A1 (en) * | 2006-05-15 | 2007-11-22 | Wisconsin Alumni Research Foundation | Pulmonary delivery of 1.alpha.,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin |
US8916195B2 (en) * | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
US8642727B2 (en) | 2006-11-08 | 2014-02-04 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (GLP-2) analogues |
KR101479324B1 (ko) | 2006-11-09 | 2015-01-05 | 오렉시젠 세러퓨틱스 인크. | 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형 |
MX343867B (es) | 2006-11-09 | 2016-11-25 | Orexigen Therapeutics Inc | Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso. |
EP2124907B1 (en) | 2007-03-19 | 2018-05-30 | Vita Sciences, Llc | Transdermal patch and method for delivery of vitamin b12 |
US20100204116A1 (en) * | 2007-09-11 | 2010-08-12 | Dorian Bevec | Use of calcitonin as anti-angiogenic agent |
CA2725930A1 (en) * | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
WO2010042145A1 (en) * | 2008-09-19 | 2010-04-15 | Nektar Therapeutics | Polymer conjugates of glp-2-like peptides |
AU2009292643B2 (en) | 2008-09-19 | 2016-02-18 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
CA2740685C (en) | 2008-10-17 | 2018-09-11 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a glp-1 agonist |
EP2480246A4 (en) | 2009-09-23 | 2013-02-27 | Biokier Inc | COMPOSITION AND METHOD FOR THE TREATMENT OF DIABETES |
EP2311486A1 (en) * | 2009-10-07 | 2011-04-20 | Nestec S.A. | GLP-2 for use in intestine and muscle recovery |
JP5973918B2 (ja) | 2009-11-13 | 2016-08-23 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Glp−1アゴニスト及びメチオニンを含む薬学的組成物 |
AU2010317995B2 (en) | 2009-11-13 | 2014-04-17 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine |
US9248123B2 (en) | 2010-01-11 | 2016-02-02 | Orexigen Therapeutics, Inc. | Methods of providing weight loss therapy in patients with major depression |
AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
JP6199186B2 (ja) | 2010-08-30 | 2017-09-20 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 2型糖尿病の治療用の医薬の製造のためのave0010の使用 |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
CA2835147A1 (en) * | 2011-05-24 | 2012-11-29 | Polyvalor S.E.C. | Compositions and methods for efficacious and safe delivery of sirna using specific chitosan-based nanocomplexes |
RU2650616C2 (ru) | 2011-08-29 | 2018-04-16 | Санофи-Авентис Дойчланд Гмбх | Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
MX356958B (es) | 2012-05-03 | 2018-06-20 | Zealand Pharma As | Análogos de péptido-2 tipo glucagón (glp-2). |
AU2013271622B2 (en) | 2012-06-06 | 2018-03-01 | Nalpropion Pharmaceuticals Llc | Methods of treating overweight and obesity |
US10092513B2 (en) | 2013-04-03 | 2018-10-09 | Sanofi | Treatment of diabetes mellitus by long-acting formulations of insulins |
US10493042B2 (en) | 2013-08-01 | 2019-12-03 | University-Industry Cooperation Group Of Kyung Hee University | Method for preventing or treating diabetes mellitus, and method for screening for diabetes mellitus therapeutic agent |
WO2015016682A1 (ko) * | 2013-08-01 | 2015-02-05 | 경희대학교 산학협력단 | 당뇨병 예방 또는 치료용 약학적 조성물, 당뇨병 예방 또는 치료 방법, 및 당뇨병 치료제 스크리닝 방법 |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
HRP20230470T1 (hr) | 2014-12-12 | 2023-07-21 | Sanofi-Aventis Deutschland Gmbh | Formulacija fiksnog omjera inzulin glargin/liksisenatid |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
WO2016205701A1 (en) | 2015-06-19 | 2016-12-22 | University Of Southern California | Enteral fast access tract platform system |
CA2990230A1 (en) | 2015-06-19 | 2016-12-22 | University Of Southern California | Compositions and methods for modified nutrient delivery |
WO2018009778A1 (en) * | 2016-07-07 | 2018-01-11 | Baylor College Of Medicine | Combination of glp-1 and glp-2 for treating or preventing metabolic diseases, disorders and syndromes |
US10774127B2 (en) | 2016-10-12 | 2020-09-15 | University Of Copenhagen | Peptide dual agonists of GIPR and GLP2R |
CN117384274A (zh) | 2016-12-09 | 2024-01-12 | 西兰制药公司 | 酰化的glp-1/glp-2双重激动剂 |
WO2019072963A1 (en) | 2017-10-12 | 2019-04-18 | University Of Copenhagen | POLYTHERAPY FOR THE TREATMENT OF BONE DISEASES |
EP3699187A1 (en) | 2019-02-21 | 2020-08-26 | Universite D'angers | Peptide targeting gip and glp-2 receptors for treating bone disorders |
US20210187077A1 (en) * | 2019-12-23 | 2021-06-24 | Idaho State University | GLP-1 Agonist Conjugates for Sustained Glycemic Control |
KR20210082120A (ko) * | 2019-12-24 | 2021-07-02 | 한미약품 주식회사 | Glp-2 또는 이의 결합체를 포함하는 골 대사성 질환에 대한 예방 또는 치료용 약학적 조성물 |
KR20220041765A (ko) * | 2020-09-25 | 2022-04-01 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 골 질환에 대한 예방 또는 치료용 약학적 조성물 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3750402T3 (de) | 1986-05-05 | 1997-04-10 | Gen Hospital Corp | Insulinotropes hormon. |
ATE193541T1 (de) | 1989-03-20 | 2000-06-15 | Gen Hospital Corp | Insulinotropes hormon |
CA2073856C (en) | 1990-01-24 | 2002-12-03 | Douglas I. Buckley | Glp-1 analogs useful for diabetes treatment |
PT101031B (pt) | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | Processo para o fornecimento de proteinas por terapia genetica |
US5512459A (en) | 1993-07-20 | 1996-04-30 | Bionebraska, Inc. | Enzymatic method for modification or recombinant polypeptides |
US5789379A (en) | 1995-04-14 | 1998-08-04 | Allelix Biopharmaceutical Inc. | Glucagon-like peptide-2 analogs |
US5834428A (en) | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
US5990077A (en) | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
US6184201B1 (en) | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
US5912229A (en) | 1996-03-01 | 1999-06-15 | Novo Nordisk Als | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
ATE505485T1 (de) * | 1996-03-01 | 2011-04-15 | Novo Nordisk As | Appetithemmendes peptid, zusammensetzung und verwendung |
EP2218734B1 (en) | 1996-04-12 | 2013-06-05 | 1149336 Ontario Inc. | Glucagon-like peptide-2 analogs |
DK0909312T3 (da) | 1996-07-05 | 2003-03-17 | Novo Nordisk As | Fremgangsmåde til fremstilling af polypeptider |
US5994500A (en) | 1996-07-19 | 1999-11-30 | 1149336 Ontario Inc. | Antagonists of intestinotrophic GLP-2 peptides |
AU4112497A (en) | 1996-08-30 | 1998-03-19 | Novo Nordisk A/S | Glp-2 derivatives |
US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
AU5696298A (en) | 1996-12-06 | 1998-06-29 | Amgen, Inc. | Keratinocyte growth factors and uses thereof |
US5952301A (en) | 1996-12-10 | 1999-09-14 | 1149336 Ontario Inc. | Compositions and methods for enhancing intestinal function |
DK0946591T3 (da) | 1996-12-13 | 2007-08-13 | Nps Allelix Corp | Klonede glucagon-lignende peptid-2 receptorer |
US6077949A (en) | 1996-12-13 | 2000-06-20 | Allelix Biopharmaceuticals, Inc. | Cloned glucagon-like peptide 2 receptors |
US6051557A (en) | 1997-05-16 | 2000-04-18 | 1149336 Ontario Inc. | Methods of enhancing functioning of the upper gastrointestinal tract |
AU746633B2 (en) * | 1997-05-16 | 2002-05-02 | 1149336 Ontario Inc. | Methods of enhancing functioning of the upper gastrointestinal tract |
AU8671798A (en) | 1997-07-30 | 1999-02-22 | Betagene, Inc. | Methods and compositions relating to no-mediated cytotoxicity |
JP2001516765A (ja) | 1997-09-12 | 2001-10-02 | ヴォルフ ゲオルグ フォースマン | 真性糖尿病及び肥満の治療のための組成物 |
EP1049790A1 (en) | 1998-01-23 | 2000-11-08 | Novo Nordisk A/S | Process for making desired polypeptides in yeast |
JP2002501889A (ja) | 1998-02-02 | 2002-01-22 | トラスティーズ オブ タフツ カレッジ | グルコース代謝を調節する方法、およびそれに関連する試薬 |
JP2002504527A (ja) | 1998-02-27 | 2002-02-12 | ノボ ノルディスク アクティーゼルスカブ | 部分的に組織化したミセル様凝集物を形成する25%を越えるヘリックス成分を有するglp−2誘導体 |
WO1999046283A1 (en) | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
FR2777283B1 (fr) * | 1998-04-10 | 2000-11-24 | Adir | Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO1999058144A1 (en) | 1998-05-11 | 1999-11-18 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
AU5480199A (en) | 1998-08-21 | 2000-03-14 | Point Therapeutics, Inc. | Regulation of substrate activity |
US6193997B1 (en) | 1998-09-27 | 2001-02-27 | Generex Pharmaceuticals Inc. | Proteinic drug delivery system using membrane mimetics |
EP1119625B1 (en) | 1998-10-07 | 2005-06-29 | Medical College Of Georgia Research Institute, Inc. | Glucose-dependent insulinotropic peptide for use as an osteotropic hormone |
US6416737B1 (en) * | 1998-11-19 | 2002-07-09 | Board Of Trustees Of The University Of Arkansas | Increasing bone strength with selected bisphosphonates |
CZ295891B6 (cs) * | 1998-12-07 | 2005-11-16 | Societe De Conseils De Recherches Et D'application | Analogy GLP-1, substituované na pozici 35, jejich použití a farmaceutické prostředky je obsahující |
CZ303399B6 (cs) * | 1998-12-07 | 2012-08-29 | Ipsen Pharma S.A.S. | Peptidový analog GLP-1 a farmaceutický prostredek jej obsahující |
CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
US6271200B1 (en) | 1998-12-21 | 2001-08-07 | Generex Pharmaceuticals Inc. | Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles |
WO2000042026A1 (en) | 1999-01-15 | 2000-07-20 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
GB9905416D0 (en) | 1999-03-09 | 1999-05-05 | Allelix Biopharma | Small molecules having GLP-2 like activity |
US6110949A (en) * | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
WO2001041779A2 (en) | 1999-12-08 | 2001-06-14 | 1149336 Ontario Inc. | Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment |
WO2001087322A2 (en) * | 2000-05-17 | 2001-11-22 | Bionebraska, Inc. | Peptide pharmaceutical formulations |
EP1294757B1 (en) * | 2000-06-16 | 2006-11-22 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
WO2002010195A2 (en) * | 2000-08-02 | 2002-02-07 | Theratechnologies Inc. | Modified peptides with increased potency |
DE60134251D1 (de) * | 2000-09-18 | 2008-07-10 | Sanos Bioscience As | Verwendung von glp-2-peptiden |
WO2002066062A2 (en) * | 2001-02-01 | 2002-08-29 | Drucker Daniel J | Enhancement of glp-2 activity |
-
2001
- 2001-09-17 DE DE60134251T patent/DE60134251D1/de not_active Expired - Lifetime
- 2001-09-17 AU AU2002213925A patent/AU2002213925A1/en not_active Abandoned
- 2001-09-17 ES ES01982302T patent/ES2310192T3/es not_active Expired - Lifetime
- 2001-09-17 DK DK01982302T patent/DK1326630T3/da active
- 2001-09-17 EP EP01982302A patent/EP1326630B1/en not_active Expired - Lifetime
- 2001-09-17 EP EP08156283A patent/EP1970072A1/en not_active Withdrawn
- 2001-09-17 US US09/954,304 patent/US6770620B2/en not_active Expired - Fee Related
- 2001-09-17 WO PCT/EP2001/010714 patent/WO2002022151A2/en active IP Right Grant
- 2001-09-17 AT AT01982302T patent/ATE396738T1/de active
- 2001-09-17 PT PT01982302T patent/PT1326630E/pt unknown
- 2001-09-17 JP JP2002526401A patent/JP5161412B2/ja not_active Expired - Fee Related
- 2001-09-18 AU AU2001287892A patent/AU2001287892A1/en not_active Abandoned
- 2001-09-18 EP EP01967517A patent/EP1414486B1/en not_active Expired - Lifetime
- 2001-09-18 PT PT01967517T patent/PT1414486E/pt unknown
- 2001-09-18 AT AT01967517T patent/ATE466592T1/de active
- 2001-09-18 JP JP2002528284A patent/JP5189723B2/ja not_active Expired - Fee Related
- 2001-09-18 DE DE60142084T patent/DE60142084D1/de not_active Expired - Lifetime
- 2001-09-18 WO PCT/GB2001/004178 patent/WO2002024214A2/en active Application Filing
- 2001-09-18 DK DK01967517.2T patent/DK1414486T3/da active
- 2001-09-18 ES ES01967517T patent/ES2345874T3/es not_active Expired - Lifetime
-
2003
- 2003-03-18 US US10/391,460 patent/US6943151B2/en not_active Expired - Fee Related
-
2008
- 2008-08-13 CY CY20081100866T patent/CY1108263T1/el unknown
-
2010
- 2010-07-30 CY CY20101100721T patent/CY1110721T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ES2310192T3 (es) | 2009-01-01 |
PT1326630E (pt) | 2008-09-02 |
JP2004508410A (ja) | 2004-03-18 |
CY1108263T1 (el) | 2014-02-12 |
DK1414486T3 (da) | 2010-08-30 |
EP1414486B1 (en) | 2010-05-05 |
EP1326630B1 (en) | 2008-05-28 |
PT1414486E (pt) | 2010-07-21 |
WO2002024214A3 (en) | 2004-02-19 |
ATE466592T1 (de) | 2010-05-15 |
US20040082507A1 (en) | 2004-04-29 |
WO2002022151A2 (en) | 2002-03-21 |
US20020037836A1 (en) | 2002-03-28 |
WO2002024214A2 (en) | 2002-03-28 |
EP1414486A2 (en) | 2004-05-06 |
ES2345874T3 (es) | 2010-10-05 |
DE60142084D1 (de) | 2010-06-17 |
AU2002213925A1 (en) | 2002-03-26 |
EP1970072A1 (en) | 2008-09-17 |
CY1110721T1 (el) | 2015-06-10 |
AU2001287892A1 (en) | 2002-04-02 |
US6770620B2 (en) | 2004-08-03 |
JP2004524268A (ja) | 2004-08-12 |
JP5161412B2 (ja) | 2013-03-13 |
ATE396738T1 (de) | 2008-06-15 |
EP1326630A2 (en) | 2003-07-16 |
WO2002022151A3 (en) | 2003-03-13 |
DE60134251D1 (de) | 2008-07-10 |
JP5189723B2 (ja) | 2013-04-24 |
US6943151B2 (en) | 2005-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1326630T3 (da) | Anvendelse af GLP-2-peptider | |
EA200300026A1 (ru) | Аналоги глюкагоноподобного пептида-1 | |
CY1112687T1 (el) | Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες | |
TR200202194T2 (tr) | Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri | |
BR0214972B1 (pt) | artigo absorvente. | |
DK1282611T3 (da) | Substituerede phenylacetatamider og anvendelse deraf som glucokinaseaktivatorer | |
DE60121988D1 (de) | Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln | |
DE60127876D1 (de) | Steuerbare Schlaufenstruktur | |
DK1349856T3 (da) | Isoindolin-1-on-glucokinase-aktivatorer | |
BR0100865B1 (pt) | artigo absorvente. | |
BR0103836B1 (pt) | artigo absorvente. | |
BR0100961B1 (pt) | artigo absorvente. | |
SE9904377D0 (sv) | Pharmaceutical combinations | |
AU2003251529A8 (en) | Planetarium and point light source for the use in same | |
MXPA03001826A (es) | Derivados de arilpiperazina. | |
DE60217991D1 (de) | Mit Wasser entfärbbarer bedruckter Artikel sowie mit Wasser entfärbbares Spielzeug mit demselben | |
CY1106200T1 (el) | Αντισωματα εναντια σε κασπαση-8, παρασκευη και χρηση τους | |
BR0212092B1 (pt) | artigo absorvente. | |
ES1045661Y (es) | Vela o fuente calorifera. | |
ES1046482Y (es) | Mesa transportable perfeccionada. | |
ES1048822Y (es) | Mesa plegable perfeccionada. | |
ES1046650Y (es) | Cartel luminoso perfeccionado. | |
ES1045547Y (es) | Botellero perfeccionado. | |
ES1046636Y (es) | Cinturones ortopedicos hinchables. | |
ES1043962Y (es) | Pata oscilante para somieres y similares. |